In some experiments, receptor-neutralizing mAbs, previously tested to block NKp46, NKp30, NKG2D, and DNAM-1 receptors in melanoma (28) and renal carcinoma (29) were used (Figure 4B, middle panel). Here, NCR1 is linked to renal carcinoma.